quinidine has been researched along with rifampin in 54 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 6 (11.11) | 18.7374 |
1990's | 5 (9.26) | 18.2507 |
2000's | 16 (29.63) | 29.6817 |
2010's | 25 (46.30) | 24.3611 |
2020's | 2 (3.70) | 2.80 |
Authors | Studies |
---|---|
Abe, T; Itoh, T; Kato, Y; Kusuhara, H; Meier, PJ; Shitara, Y; Sugiyama, D; Sugiyama, Y | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Hashizume, H; Kawasaki, M; Komatsu, M; Matsumoto, M; Sasaki, H; Shimokawa, Y; Tomishige, T; Tsubouchi, H | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
Glen, RC; Lowe, R; Mitchell, JB | 1 |
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Ahlin, G; Bergström, F; Bredberg, U; Fridén, M; Hammarlund-Udenaes, M; Rehngren, M; Wan, H | 1 |
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
Ebner, T; Ishiguro, N; Kishimoto, W; Schaefer, O; Shimizu, H | 1 |
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Carazo, A; Drechslerová, M; Hrušková, ZR; Hyrsova, L; Kuneš, J; Nova, A; Pavek, P; Pour, M; Smutny, T; Špulák, M | 1 |
Cleghorn, LAT; Davis, S; Epemolu, O; Ferguson, L; Green, SR; Guijarro, L; Hipskind, P; Huggett, M; Korkegian, A; Kumar, A; Lopez Moure, A; Masquelin, T; Odingo, J; Parish, T; Ray, PC; Read, KD; Riley, J; Rullas, J; Scullion, P; Shishikura, Y; Smith, A; Turner, P; Wescott, H; Wilson, C; Wyatt, PG; Zuccotto, F | 1 |
Fu, L; Huang, H; Li, G; Li, Y; Liu, Y; Lu, H; Lu, Y; Ma, C; Sheng, L; Wang, B; Zhang, B; Zhang, D; Zhao, H | 1 |
Ahmad, D; Ahuja, S; Carruthers, G; Henderson, R; Mathur, P | 1 |
Baciewicz, AM; Self, TH | 1 |
Risler, T; Seipel, L | 1 |
Brown, JR; Schwartz, A | 1 |
Bussey, HI; Hill, EG; Merritt, GJ | 1 |
Carruthers, SG; Twum-Barima, Y | 1 |
Gibaldi, M | 1 |
Bachmann, KA; Jauregui, L | 1 |
Coville, PF; Walker, RJ; Wanwimolruk, S; Wong, SM; Zhang, H | 1 |
Allen, LV; Erickson, MA | 1 |
Brøsen, K; Damkier, P; Hansen, LL | 1 |
Adedoyin, A; Branch, RA; Frye, RF; Romkes, M; Wilson, JW | 1 |
Bigler, L; Follath, F; Ha, HR; Kozlik, P; Stieger, B | 1 |
Drescher, S; Eichelbaum, M; Fromm, MF; Glaeser, H; Hitzl, M; Mürdter, T | 1 |
Pollack, GM; Zong, J | 1 |
Benet, LZ; Lau, YY; Okochi, H; Wu, CY | 1 |
Bidstrup, TB; Brøsen, K; Damkier, P; Scharling, B; Stilling, N; Thomsen, MS | 1 |
Gundu, J; Machavaram, KK; Yamsani, MR | 1 |
Hangaishi, A; Kurokawa, M | 1 |
Padowski, JM; Pollack, GM | 1 |
Be, X; Berry, L; Chen, A; Huang, L; Janosky, B; Lin, MH; Roberts, J | 1 |
Andersson, TB; Bäckström, T; Bertilsson, L; Björkhem-Bergman, L; Bredberg, E; Diczfalusy, U; Nylén, H; Rönquist-Nii, Y | 1 |
Collier, AC; Deo, AK; Domino, KB; Eary, JF; Hsiao, P; Link, JM; Liu, L; Mankoff, DA; Spiekerman, CF; Unadkat, JD | 1 |
Jung, JA; Parvez, MM; Shin, HJ; Shin, JG | 1 |
Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S | 1 |
Costales, C; Eatemadpour, S; Kimoto, E; Lazzaro, S; Varma, MV; Yamazaki, S | 1 |
Asaumi, R; Nunoya, KI; Sugiyama, Y; Taskar, KS; Yamaura, Y | 1 |
5 review(s) available for quinidine and rifampin
Article | Year |
---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Rifampin drug interactions.
Topics: Anticoagulants; Barbiturates; Contraceptives, Oral; Cytochrome P-450 Enzyme System; Digitoxin; Drug Interactions; Endoplasmic Reticulum; Enzyme Induction; Female; Glucocorticoids; Humans; Hypoglycemic Agents; Male; Methadone; Pregnancy; Quinidine; Rifampin | 1984 |
Stereoselective and isozyme-selective drug interactions.
Topics: Cimetidine; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Isoenzymes; Quinidine; Rifampin; Stereoisomerism; Warfarin | 1993 |
[Drug-induced thrombocytopenia].
Topics: Abciximab; Antibodies, Monoclonal; Carbamazepine; Gold Compounds; Heparin; Humans; Immunoglobulin Fab Fragments; Platelet Glycoprotein GPIIb-IIIa Complex; Procainamide; Quinidine; Quinine; Rifampin; Thrombocytopenia; Time Factors | 2007 |
4 trial(s) available for quinidine and rifampin
Article | Year |
---|---|
Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo.
Topics: Administration, Oral; Adult; Antipyrine; Aryl Hydrocarbon Hydroxylases; Carbamazepine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Ethosuximide; Humans; Liver; Lorazepam; Male; Oxidoreductases, N-Demethylating; Phenobarbital; Phenytoin; Quinidine; Rifampin; Smoking; Theophylline; Valproic Acid | 1993 |
Rifampicin treatment greatly increases the apparent oral clearance of quinidine.
Topics: Administration, Oral; Adult; Antibiotics, Antitubercular; Area Under Curve; Cytochrome P-450 Enzyme System; Enzyme Induction; Half-Life; Humans; Male; Quinidine; Reference Values; Rifampin | 1999 |
Rifampicin seems to act as both an inducer and an inhibitor of the metabolism of repaglinide.
Topics: Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Carbamates; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Humans; Hydrocortisone; Hypoglycemic Agents; Male; Middle Aged; Piperidines; Quinidine; Rifampin; Time Factors | 2004 |
Quinine compared to 4β-hydroxycholesterol and midazolam as markers for CYP3A induction by rifampicin.
Topics: Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Hydrocortisone; Hydroxycholesterols; Midazolam; Quinidine; Quinine; Rifampin | 2014 |
45 other study(ies) available for quinidine and rifampin
Article | Year |
---|---|
Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.
Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antibiotics, Antitubercular; Antimalarials; Biological Transport, Active; Digoxin; Enzyme Inhibitors; Estradiol; Ibuprofen; LLC-PK1 Cells; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Quinidine; Quinine; Rats; Rifampin; Swine | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
Topics: Animals; Antitubercular Agents; Blood; Cell Line; Humans; In Vitro Techniques; Intracellular Membranes; Macrophages; Mammals; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium; Mycobacterium bovis; Mycolic Acids; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
Topics: Animals; Biological Transport; Brain; Chemical Phenomena; Dialysis; Hydrogen-Ion Concentration; In Vitro Techniques; Lysosomes; Male; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Reproducibility of Results; Tissue Distribution | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Base Sequence; Dipeptidyl-Peptidase IV Inhibitors; DNA Primers; Drug Evaluation, Preclinical; Drug Interactions; HEK293 Cells; Humans; In Vitro Techniques; Linagliptin; LLC-PK1 Cells; Purines; Quinazolines; Swine | 2013 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.
Topics: Constitutive Androstane Receptor; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hep G2 Cells; Hepatocytes; Humans; Models, Molecular; Molecular Structure; Quinazolines; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship | 2016 |
Identification of Morpholino Thiophenes as Novel Mycobacterium tuberculosis Inhibitors, Targeting QcrB.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Cytochromes c; Mice; Morpholines; Mycobacterium tuberculosis; Oxidoreductases; Structure-Activity Relationship; Thiophenes; Vero Cells | 2018 |
Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.
Topics: Animals; Chlorocebus aethiops; Drug Design; Female; Hep G2 Cells; Humans; Mice; Microbial Sensitivity Tests; Molecular Conformation; Mycobacterium tuberculosis; Oxazolidinones; Safety; Tuberculosis, Multidrug-Resistant; Vero Cells | 2020 |
Rifampicin-quinidine interaction.
Topics: Aged; Drug Interactions; Humans; Male; Quinidine; Rifampin | 1979 |
[Controlled digitalis therapy].
Topics: Cholestyramine Resin; Digitalis Glycosides; Digitoxin; Digoxin; Dose-Response Relationship, Drug; Drug Interactions; Heart Failure; Humans; Patient Compliance; Phenobarbital; Quinidine; Rifampin | 1983 |
Quinidine-rifampin interaction.
Topics: Aged; Arrhythmias, Cardiac; Drug Interactions; Humans; Male; Quinidine; Rifampin | 1984 |
The influence of rifampin on quinidine and digoxin.
Topics: Aged; Arrhythmias, Cardiac; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Humans; Kinetics; Middle Aged; Quinidine; Rifampin; Tuberculosis, Pulmonary | 1984 |
Quinidine-rifampin interaction.
Topics: Administration, Oral; Adult; Antipyrine; Drug Interactions; Half-Life; Humans; Injections, Intravenous; Kinetics; Liver; Male; Quinidine; Rifampin | 1981 |
Metabolism of quinine in man: identification of a major metabolite, and effects of smoking and rifampicin pretreatment.
Topics: Antimalarials; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Glucuronates; Humans; Quinidine; Quinine; Rifampin; Smoking | 1995 |
Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids.
Topics: Administration, Oral; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antimalarials; Antitubercular Agents; Bethanechol; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Stability; Humans; Muscarinic Agonists; Pyrazinamide; Quinidine; Rifampin; Suspensions; Tetracycline | 1998 |
In vivo modulation of CYP enzymes by quinidine and rifampin.
Topics: Acetylation; Administration, Oral; Adrenergic alpha-Antagonists; Adult; Anti-Arrhythmia Agents; Antibiotics, Antitubercular; Anticonvulsants; Aryl Hydrocarbon Hydroxylases; Caffeine; Central Nervous System Stimulants; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2E1; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dapsone; Debrisoquin; Drug Administration Schedule; Enzyme Inhibitors; Humans; Male; Mephenytoin; Mixed Function Oxygenases; Quinidine; Reference Values; Rifampin; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases; Theophylline | 2000 |
Metabolism of amiodarone (Part III): identification of rabbit cytochrome P450 isoforms involved in the hydroxylation of mono-N-desethylamiodarone.
Topics: Amiodarone; Animals; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Aryl Hydrocarbon Hydroxylases; Benzoflavones; Chromatography, High Pressure Liquid; Cimetidine; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ketoconazole; Kinetics; Microsomes, Liver; Midazolam; Models, Chemical; Oxidoreductases, N-Demethylating; Protein Isoforms; Quinidine; Rabbits; Rifampin; Time Factors | 2001 |
P-glycoprotein-mediated intestinal and biliary digoxin transport in humans.
Topics: Adult; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Biological Transport, Active; Cardiotonic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Digoxin; Dose-Response Relationship, Drug; Fluorescence Polarization Immunoassay; Humans; Infusions, Intravenous; Intestinal Absorption; Jejunum; Male; Quinidine; Reference Values; Rifampin | 2003 |
Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
Topics: Animals; Antibiotics, Antitubercular; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Brain; Dose-Response Relationship, Drug; Drug Interactions; Mice; Perfusion; Quinidine; Rifampin; Verapamil | 2003 |
Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay.
Topics: Animals; Biological Transport; Digoxin; Liver; Male; Membrane Transport Proteins; Perfusion; Quinidine; Rats; Rats, Sprague-Dawley; Rifampin | 2004 |
Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Butyrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Doxorubicin; Enzyme Induction; Enzyme Inhibitors; Erythromycin; Etoposide; Indinavir; Infusions, Intravenous; Isoenzymes; Ketoconazole; Male; Nitrendipine; Quinidine; Rats; Rats, Wistar; Rifampin; Sulfobromophthalein | 2004 |
Examination of the ability of the nasal administration route to confer a brain exposure advantage for three chemical inhibitors of P-glycoprotein.
Topics: Acridines; Administration, Intranasal; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Brain; Drug Delivery Systems; Mice; Quinidine; Rifampin; Tetrahydroisoquinolines | 2010 |
Use of uptake intrinsic clearance from attached rat hepatocytes to predict hepatic clearance for poorly permeable compounds.
Topics: Animals; Bosentan; Capillary Permeability; Chromatography, Liquid; Cyclosporine; Dogs; Fluorobenzenes; Hepatocytes; Madin Darby Canine Kidney Cells; Male; Metabolic Clearance Rate; Pyrimidines; Quinidine; Rats; Rats, Sprague-Dawley; Rifampin; Rosuvastatin Calcium; Sulfonamides; Tandem Mass Spectrometry; Verapamil; Xenobiotics | 2012 |
Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.
Topics: Adult; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cerebrovascular Circulation; Cross-Over Studies; Female; Humans; Macaca; Male; Positron-Emission Tomography; Quinidine; Rats; Rifampin; Young Adult | 2015 |
Evaluation of
Topics: Aminosalicylic Acid; Anti-Inflammatory Agents, Non-Steroidal; Antitubercular Agents; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Cimetidine; Drug Interactions; HEK293 Cells; Humans; Ibuprofen; Liver-Specific Organic Anion Transporter 1; Naproxen; Octamer Transcription Factor-1; Organic Anion Transport Protein 1; Organic Anion Transporters, Sodium-Independent; Organic Cation Transporter 2; Probenecid; Proton Pump Inhibitors; Quinidine; Rifampin; Verapamil | 2017 |
Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.
Topics: Ciprofloxacin; Clarithromycin; Computer Simulation; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inducers; Drug Interactions; Fluconazole; Humans; Itraconazole; Ketoconazole; Models, Biological; Paroxetine; Quinidine; Rifampin; Software | 2018 |
Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction.
Topics: Administration, Oral; ATP Binding Cassette Transporter, Subfamily B, Member 1; Dabigatran; Digoxin; Drug Interactions; Female; Gene Expression Regulation; Healthy Volunteers; Humans; Intestinal Mucosa; Male; Models, Biological; Propanolamines; Quinidine; Rifampin | 2019 |
Robust physiologically based pharmacokinetic model of rifampicin for predicting drug-drug interactions via P-glycoprotein induction and inhibition in the intestine, liver, and kidney.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Digoxin; Drug Interactions; Humans; Intestines; Kidney; Liver; Membrane Transport Proteins; Models, Biological; Quinidine; Rifampin | 2022 |